Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to assess the rate of major molecular response (MMR), defined as BCR-ABL transcripts <0.1% on International Scale (IS) at 12 months after dasatinib discontinuation in patients who have maintained MMR without re-starting dasatinib treatment
Critère d'inclusion
- Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) with stable Complete Molecular Response (CMR) who have received dasatinib as first or second-line treatment for a minimum of 2 years at the time of enrollment and have confirmed dasatinib induced complete molecular remission